Forte Biosciences, Inc. (37T)
XSTU 
Summary
37T Chart
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.
Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting platform potential beyond a single indication. FB102's mechanism targets CD122, modulating key immune pathways, with placebo-controlled data showing 21.7% F-VASI benefit in vitiligo and histologic protection in celiac disease. FBRX holds a pro forma cash position of ~$220M post-financing, providing 11–12 quarters of runway to advance Phase II/III trials across multiple autoimmune indications.
Forte Biosciences, Inc. (37T) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Forte Biosciences, Inc. ever had a stock split?
Forte Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Paul A. Wagner CEO | XSTU Exchange | US34962G2084 ISIN |
| US Country | 22 Employees | 16 Jun 2020 Last Dividend | 28 Aug 2024 Last Split | - IPO Date |
